Precision Medicine & Digital Health Leader, Data scientist, Great boss award, Force multiplier, Service to America award, Startup & NonProfit Board Governance
Georgetown University
Joined October 2009
- Tweets1.8K
- Following998
- Followers1.1K
- Likes2.6K
Subha Madhavan retweeted
Leading experts discuss applications, pitfalls, and future directions for applications of AI in oncology in the AI for Oncology, Precision Medicine, and Health track @ Bio-IT this May! bio-itworldexpo.com/?utm_med…
#BioIT22
@bioitworld
#medicine #research #health #ai
@subhamadhavan
Subha Madhavan retweeted
#DigitalHealth COVID-19 Impact Assessment: Lessons Learned and Compelling Needs
In @theNAMedicine by @peteratmsr, @dramyabernethy , @DShaywitz, Adi Gundlapalli, Jim Weinstein, P. Murali Doraiswamy, @kevin_schulman, & @subhamadhavan
nam.edu/digital-health-covid…
Subha Madhavan retweeted
Invited Speaker @subhamadhavan presented incredibly innovative work at #CGCAnnual2021 using #AI, #NLP, and expert crowdsourcing approaches to enable precision medicine, match patients to trials, automatically identify adverse events, and standardize curation of somatic variants.
Subha Madhavan retweeted
The future of Clinical Trials: how #AI, #BigTech, & #Covid19 could make drug development cheaper, faster & more effective #DX #ML
V/@CBinsights @GersonRolim @intellimetri
cbinsights.com/research/clin…
#100DaysOfCode #WomenWhoCode #100DaysOfMLCode #HealthTech #Coding #Chatbot #Python
Subha Madhavan retweeted
Congratulations to @Georgetown_HIDS alumni Fuyuan Wang! He recently joined @FredNatLab subcontractor Essential Software as Software Engineer.
Apply to our one year industry driven #HealthInformatics & #DataScience Masters Program. Deadline July 1st: lnkd.in/ejrdtg6
Subha Madhavan retweeted
Great #Nexusinformatics talk by @subhamadhavan describing virtual molecular tumor board.
Subha Madhavan retweeted
Loving the first keynote from @subhamadhavan of @ICBI_Georgetown on Virtual Molecular Tumor Boards at the #NexusInformatics Conference with @BioNexusKC @ChildrensMercy @clevelandunivkc @KansasCityU
Subha Madhavan retweeted
🌟"Envisioning the future of precision oncology trials" by @subhamadhavan &Co @NatureCancer
Find it at:
go.nature.com/3cLhNb5
#11F #WomenInScience #WomenAndGirlsInScience @UN_Women
Subha Madhavan retweeted
Yes, molecular tumor boards can add significant value at many levels
#TumorBoardTuesday
Sorry for the shameless self plug
@subhamadhavan @edikb @Perthera
JAMIA Open. 2019 Oct 7;2(4):505-515. doi: 10.1093/jamiaopen/ooz045. eCollection 2019 Dec.
Subha Madhavan retweeted
🚀 @MIT Intro to #DeepLearning 2021 is kicking off! 🚀
With over 700 MIT students and over 20,000 students registered world-wide, don't miss this year's iteration! 🤩
🧠 New lecture every FRIDAY at 1PM ET!
😍 #FREE for everyone!
💻 introtodeeplearning.com
@xanamini @apsoleimany
Subha Madhavan retweeted
Humbled and excited to serve as WH science advisor for President-elect @JoeBiden. He has assembled a diverse team of brilliant scientists and is elevating the role of science. So much to be done, and it will take everyone working together. #Scienceisback!
Subha Madhavan retweeted
"Precision oncology still hinges on the application of cancer therapies that are designed for the ‘average patient’... Since there is no ‘average patient’, targeted treatments are successful only in some patients."
nature.com/articles/s43018-0…
Nice review @subhamadhavan @MathCancer!
Subha Madhavan retweeted
Virtual molecular tumor boards (VMTB) enable precision oncology by integrating variables like molecular profile, treatment history, cancer gene variants, biomarker-treatment associations, and current treatment guidelines. Excellent paper by @subhamadhavan et al in @NatureCancer
“Envisioning the future of precision #oncology trials” @NatureCancer @subhamadhavan et al. discuss opportunities to improve cohort selection and trial enrollment for the future of PO trials! Excellent review of the current and future landscape ! @OncoAlert go.nature.com/3ng4ukF
Subha Madhavan retweeted
“Envisioning the future of precision #oncology trials” @NatureCancer @subhamadhavan et al. discuss opportunities to improve cohort selection and trial enrollment for the future of PO trials! Excellent review of the current and future landscape ! @OncoAlert go.nature.com/3ng4ukF
Subha Madhavan retweeted
#ESMO20 Happy to share the first results of RAIN-701, a phase II study of #tarloxotinib in patients with NSCLC harboring an #EGFR exon 20 insertion or an activating #HER2 mutation and any solid tumor with an #NRG1 or ERBB gene fusion. #LCSM @OncoAlert
Subha Madhavan retweeted
The world's largest #biomedical #library has a new handle! @NLM_NIH will have all the latest news and happenings from the National Library of Medicine.
Subha Madhavan retweeted
Tune in on Friday Oct 30th to watch a #panel discussion on #health and #biomedical #research #data #ethics moderated by @Georgetown_HIDS Director @subhamadhavan. Zoom link: georgetown.zoom.us/j/9328440…
Subha Madhavan retweeted
@ICBI_Georgetown is hosting a free Health & Biomedical Research Data Ethics panel this Friday 10/30 at 10:30 AM EST, moderated by @subhamadhavan | georgetown.zoom.us/j/9328440…
This quoted post is unavailable.
Subha Madhavan retweeted
Overlapping symptoms may cause confusion between COVID-19 and flu, but there are some key differences. What you should know: cle.clinic/3m4cMNn
